These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20967978)

  • 1. [Treatment of overactive bladder in women with vitaprost forte].
    Gomberg VG; Nad' IuT
    Urologiia; 2010; (4):20-5. PubMed ID: 20967978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Using terasosine (setegis) in the treatment of hyperactive urinary bladder in elderly women].
    Gomberg VG; Nad' IuT
    Urologiia; 2006; (5):63-7, 71. PubMed ID: 17444155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of Vitaprost Forte in the treatment of adenoma].
    Gomberg VG; Nad' IuT
    Urologiia; 2010; (5):35-9. PubMed ID: 21254638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electromotive drug-administration: a pilot study for minimal-invasive treatment of therapy-resistant idiopathic detrusor overactivity.
    Bach P; Wormland RT; Möhring C; Goepel M
    Neurourol Urodyn; 2009; 28(3):209-13. PubMed ID: 19205067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intravesical Resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters, and quality of life of patients with urodynamic increased bladder sensation.
    Apostolidis A; Gonzales GE; Fowler CJ
    Eur Urol; 2006 Dec; 50(6):1299-305. PubMed ID: 16697519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vitaprost-forte in the treatment of patients with prostatic adenoma].
    Shafranov DV; Mariupol'skiĭ AA
    Urologiia; 2011; (6):54, 56-9. PubMed ID: 22448483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Assessment of symptoms severity in patients with overactive bladder].
    Al'-Shukri SKh; Kuz'min IV
    Urologiia; 2008; (6):37-40. PubMed ID: 19248597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duloxetine compared with placebo for treating women with symptoms of overactive bladder.
    Steers WD; Herschorn S; Kreder KJ; Moore K; Strohbehn K; Yalcin I; Bump RC;
    BJU Int; 2007 Aug; 100(2):337-45. PubMed ID: 17511767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity.
    Ronchi P; Gravina GL; Galatioto GP; Costa AM; Martella O; Vicentini C
    Neurourol Urodyn; 2009; 28(1):52-7. PubMed ID: 18671288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
    Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
    Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG; Al-Buheissi S
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
    Schmid DM; Sauermann P; Werner M; Schuessler B; Blick N; Muentener M; Strebel RT; Perucchini D; Scheiner D; Schaer G; John H; Reitz A; Hauri D; Schurch B
    J Urol; 2006 Jul; 176(1):177-85. PubMed ID: 16753396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of overactive urinary bladder with imperative urinary incontinence in women].
    Neĭmark AI; Riapolova MV; Mel'nik MA
    Urologiia; 2010; (2):36-8. PubMed ID: 20967993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desmopressin, as a "designer-drug," in the treatment of overactive bladder syndrome.
    Hashim H; Malmberg L; Graugaard-Jensen C; Abrams P
    Neurourol Urodyn; 2009; 28(1):40-6. PubMed ID: 18726947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?
    Sahai A; Sangster P; Kalsi V; Khan MS; Fowler CJ; Dasgupta P
    BJU Int; 2009 Mar; 103(5):630-4. PubMed ID: 18990156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration.
    Wein AJ; Khullar V; Wang JT; Guan Z
    BJU Int; 2007 Feb; 99(2):360-3. PubMed ID: 17155987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sexual dysfunction in women with overactive bladder and their correction with m-cholinolytic spasmex].
    Danilova TI; Danilov VV; Luchinskiĭ SA; Danilov VV; Vasil'chenko AV
    Urologiia; 2010; (6):30-4. PubMed ID: 21433320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.